The effect of Iavbredine on pulmonary hypertension with right heart failure patient and its cost-effectiveness analysis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000034928

Enrollment

Unknown

Registered

2020-07-24

Start date

2020-08-01

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary artery hypertension

Interventions

Case series:ivabradine

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years old; 2. Diagnosed of Pulmonary hypertension by right heart catheter:mean pulmonary pressure >= 25mmHg,pulmonary capillary wedge pressure3 wood; 3. Heart rate at rest>90 beats per minute.

Exclusion criteria

Exclusion criteria: 1. Aged >=75 years; 2. use other heart rate lowering drugs such as beta blockers; 3. patients with arrhythmias such as sinus block,ventricular tachycardia or Permanent pacemaker implantation; 4. other drug contraindications; 5. severe liver and renal insufficiency; 6. poor compliance or adverse reactions; 7. recent changes in treatment.

Design outcomes

Primary

Measure	Time frame
6 minite walking distance;echocardiography;NT-proBNP;heart rate;WHO FC;EuroQol 5-Dimensions;	—

Countries

China

Contacts

Public ContactJiang Li

Second Xiangya Hospital of Central South University

lijiangcs@163.com+86 13975128898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026